PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
July 1, 1988Journal of Cardiovascular Pharmacology

Cumulative Hemodynamic Response to Short-Term Treatment with Flosequinan (BTS 49465), a New Direct-Acting Vasodilator Drug, in Severe Chronic Congestive Heart Failure

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does short-term treatment with flosequinan improve hemodynamics without tolerance in patients with severe chronic heart failure?

Population

16 patients with severe chronic heart failure

Design

Cohort

Follow-up

3 days

Authors

PKPaul KesslerMPMilton PackerNMNorma Medina

Discussion

Loading...

Member takes

Overview

Short-term therapy with flosequinan produces cumulative hemodynamic improvement without pharmacologic tolerance in patients with severe chronic heart failure.

Structured PICO

Does short-term treatment with flosequinan improve hemodynamics without tolerance in patients with severe chronic heart failure?

P
Population
16 patients with severe chronic heart failure
I
Intervention
Flosequinan (100 or 150 mg orally) daily for 3 days
O
Outcome
Hemodynamic responses including cardiac index, left ventricular filling pressure, mean right atrial pressure, and systemic vascular resistancesurrogate

Short-term therapy with flosequinan produces cumulative hemodynamic improvement without pharmacologic tolerance in patients with severe chronic heart failure.

Cite This Study

Kessler et al. (1988) studied this question.

synapsesocial.com/papers/6a72a4ed75498292b70ba433https://doi.org/10.1097/00005344-198807000-00002
View Full Paper
Ask AI
Bookmark
Share